Dow Down0.48% Nasdaq Up0.29%

XOMA Corporation (XOMA)

0.69 Down 0.01(1.82%) May 31, 4:00PM EDT
|After Hours : 0.69 0.00 (0.00%) May 31, 4:36PM EDT
ProfileGet Profile for:
XOMA Corporation
2910 Seventh Street
Berkeley, CA 94710
United States - Map
Phone: 510-204-7200

Index Membership:N/A
Full Time Employees:80

Business Summary 

XOMA Corporation, a development stage biotechnology company, discovers, develops, and commercializes antibody-based therapeutics in the United States, Europe, and the Asia Pacific. The company’s product candidates include XOMA 358, a human negative allosteric modulating insulin receptor antibody is in phase 2 proof-of-concept study for treating congenital hyperinsulinism and post-meal hypoglycemia in post-bariatric surgery patients; XOMA 129, a potent fragment of a monoclonal antibody is under preclinical testing to treat patients with acute severe hypoglycemia; XOMA 213, a allosteric inhibitor for use in treating prolactinoma and anti-psychotic-induced hyperprolactinemia. It also licenses antibody discovery, optimization, and development technologies, including Antibody Discovery Advanced Platform Technologies, ModulX, and OptimX. The company has research and development collaboration and licensing agreements with Novartis AG; Novo Nordisk A/S; Takeda Pharmaceutical Company Limited; and Pfizer Inc. XOMA Corporation was founded in 1981 and is headquartered in Berkeley, California.

Key Statistics

Company Websites 
Home Page
Search Yahoo! for:
More on XOMA Corporation

Corporate Governance 
XOMA Corporation’s ISS Governance QuickScore as of May 1, 2016 is 7. The pillar scores are Audit: 10; Board: 5; Shareholder Rights: 2; Compensation: 10.
Brought to you by Institutional Shareholder Services (ISS)

Key Executives 
Mr. John W. Varian , 56
Chief Exec. Officer and Director
Mr. Thomas Burns , 42
Chief Financial Officer and VP of Fin.
Mr. James R. Neal , 60
Chief Operating Officer and Sr. VP
Mr. Charles C. Wells , 65
VP of HR & Information Technology
Mr. Paul D. Rubin M.D., 62
Chief Medical Officer and Sr. VP of R&D
Amounts are as of Dec 31, 2015 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year.
Currency in USD.
View Insiders